We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
-1.92%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
-$227M
Cap. Flow
-$69M
Cap. Flow %
-4.99%
Top 10 Hldgs %
65.28%
Holding
52
New
8
Increased
7
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$21M
2
ELVN icon
Enliven Therapeutics
ELVN
+$16.9M
3
BBIO icon
BridgeBio Pharma
BBIO
+$13.7M
4
MGNX icon
MacroGenics
MGNX
+$10.3M
5
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$8.34M

Top Sells

Rank Stock Value
1
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$143M
2
ALLK
Allakos
ALLK
+$23.5M
3
REPL icon
Replimune Group
REPL
+$5.82M
4
KRYS icon
Krystal Biotech
KRYS
+$4.27M
5
EPIX
ESSA Pharma
EPIX
+$1.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
2 Miscellaneous 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$162M 11.71%
9,781,472
+23,113
+0.2% +$370K
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.02B
$126M 9.09%
9,341,551
– –
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$101M 7.28%
4,345,559
– –
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.05B
$95.5M 6.92%
8,684,232
– –
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.11B
$92.7M 6.71%
3,860,107
– –
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.82B
$78.3M 5.67%
3,708,838
– –
KRYS icon
7
Krystal Biotech
KRYS
$10.4B
$75.7M 5.48%
945,407
-54,330
-5% -$4.27M
PHAT icon
8
Phathom Pharmaceuticals
PHAT
$759M
$60M 4.35%
8,407,152
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$59.1M 4.28%
2,944,349
+128,629
+5% +$2.78M
PCVX icon
10
Vaxcyte
PCVX
$9.05B
$52.4M 3.79%
1,397,405
– –
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$7.09B
$38.6M 2.8%
2,164,739
+270,739
+14% +$6.8M
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
$25.5M 1.84%
3,238,859
– –
COGT icon
13
Cogent Biosciences
COGT
$6.05B
$23.3M 1.69%
2,159,154
+50,000
+2% +$640K
ALPN
14
DELISTED
Alpine Immune Sciences Inc
ALPN
$23.1M 1.67%
2,985,757
– –
TYRA icon
15
Tyra Biosciences
TYRA
$1.7B
$22.8M 1.65%
1,421,310
+93,645
+7% +$1.11M
CRNX
16
DELISTED
Crinetics Pharmaceuticals
CRNX
$22.7M 1.65%
1,414,823
– –
TARS icon
17
Tarsus Pharmaceuticals
TARS
$3.94B
$22.5M 1.63%
1,787,527
– –
THRX
18
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$20M 1.45%
2,248,194
+850,000
+61% +$8.34M
ANAB icon
19
AnaptysBio
ANAB
$1.69B
$19.6M 1.42%
899,700
– –
BBIO icon
20
BridgeBio Pharma
BBIO
$14.8B
$19.4M 1.41%
+1,171,650
New +$13.7M
RVMD icon
21
Revolution Medicines
RVMD
$45.1B
$18.5M 1.34%
+854,484
New +$21M
ELVN icon
22
Enliven Therapeutics
ELVN
$4.36B
$18.2M 1.32%
+830,983
New +$16.9M
ACAD icon
23
Acadia Pharmaceuticals
ACAD
$4.81B
$16.1M 1.17%
857,338
– –
GRTS
24
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$14.4M 1.04%
5,162,348
– –
MRUS
25
DELISTED
Merus
MRUS
$13.7M 0.99%
746,479
– –
1
2 3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2023 Portfolio in Review

As of Q1 2023, Frazier Life Sciences Management held 52 positions worth $1.38B, down 14% from $1.61B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Frazier Life Sciences Management withdrew a net $69M in Q1 2023, closing 3 positions and reducing 4 holdings. Its most notable exit was Imago BioSciences, Inc. Common stock, an estimated $143M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Frazier Life Sciences Management opened a new position in Revolution Medicines worth $18.5M.

  • Frazier Life Sciences Management's largest Q1 2023 buy was Revolution Medicines: 854,484 shares worth $18.5M.
  • Frazier Life Sciences Management added most to Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023, an estimated $8.34M increase.
  • Frazier Life Sciences Management's biggest Q1 2023 reduction was Allakos, cutting an estimated $23.5M.
  • Frazier Life Sciences Management fully exited Imago BioSciences, Inc. Common stock in Q1 2023, selling an estimated $143M.
  • Frazier Life Sciences Management's ten largest holdings make up 65% of its $1.38B portfolio in Q1 2023.
  • Frazier Life Sciences Management opened 8 new positions and closed 3 in Q1 2023.
  • Frazier Life Sciences Management's portfolio value fell 14% quarter-over-quarter to $1.38B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2023, filed 15 May 2023.